In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Coup for Nobex

Executive Summary

Large pharma companies haven't set a high priority on developing new drug delivery formulations for their existing portfolios; nor have they been interested in macromolecule development. Thus, the strategic alliance forged in May between giant GSK and small drug-delivery firm Nobex is noteworthy. Not only is it one of the largest deals of its kind, but it also focuses on development of oral insulin for diabetic patients, which presents a challenge that few have attempted to overcome.

You may also be interested in...

Teasing Out Next-Generation Diabetes Drugs

Many start-ups are developing diabetes drugs based on known targets which could attract Big Pharma partners and get to the clinic quickly, while a few invest in novel compounds that are either riskier or address the field's smaller subsets. Among the former are Phenomix, Plexxikon, CareX and Prosidion; among the latter are DiaKine, and DiaMedica. In all cases, these companies are looking to partner with Big Pharma, which is aggressively pursuing small-molecule drugs for diabetes.

Bristol: Rebuilding a Diabetes Franchise--with Insulin

The great remaining religious divide in the drug industry is between those who reject and those who accept the fundamental therapeutic and economic importance of large molecule drugs. Diabetes is the central holy site in the schism since, for the most part, companies have either made small-molecule, oral therapies, or they've made injectable insulin. Bristol-Myers' deals for sustained-release insulin (with Flamel) and inhaled insulin (with QDose) mark both Bristol's increasing embrace of the large-molecule world as well as a novel strategy in the diabetes world.

Aventis: Building on a Base in Diabetes

Aventis is looking to the diabetes market to boost future growth. Lantus, the company's novel once-a-day injectable insulin, will spearhead the move. But can Aventis use an injectable to break into the fast growing Type II segment?

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts